NCT06585969View on ClinicalTrials.gov

A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

504

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

May 31, 2029

Study Completion Date

May 31, 2029

Conditions

Metastatic Breast CancerER-positive Breast CancerLuminal BHer2 EnrichedBasal Like

Interventions

DRUG

Trastuzumab deruxtecan (T-DXd)

Trastuzumab deruxtexan every three weeks

DRUG

Ribociclib with ET

Ribociclib with endocrine therapy

DRUG

Abemaciclib with ET

Abemaciclib with endocrine therapy

All Listed Sponsors

lead

Danish Breast Cancer Cooperative Group

OTHER

NCT06585969 - A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter